October 11th 2024
The draft joint network strategy for the EU until 2028 will be open for public consultation until Nov. 30, 2024.
October 4th 2024
The agency is working with the European medicines regulatory network to improve the assessment and approval process for new medications.
September 24th 2024
Approvals were recommended for treatments of ovarian cancer, lung cancer, bleeding disorders, respiratory disease, and more.
September 23rd 2024
The agency is recommending the extension of the smallpox and mpox vaccine, Imvanex, to adolescents aged 12 to 17.
June 18th 2024
The agency is evaluating risks associated with the painkiller metamizole. It is also reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.
Europe Lifts COVID-19 Business Continuity Status
EMA and European regulators are lifting their COVID-19 business continuity measures as the pandemic’s peak ends.
EMA Recommends Adapted Spikevax Vaccine
The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.
EMA Extends Use of COVID-19 Vaccines to Children
The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.
European Commission Approves Bevacizumab Biosimilar from Celltrion Healthcare
The European Commission (EC) has approved Celltrion Healthcare's Vegzelma (CT-P16), a biosimilar to bevacizumab referencing Avastin.
Industry 1VQ Solutions: Changes That Bring an Additional Restriction on the Product Compared to Registered Conditions
A case study discussing why post-approval changes present a very low risk, and therefore can be downgraded from a prior-approval to a notification after implementation and managed in the PQS with immediate implementation effect.
EMA Recommends Eleven New Medicines
The agency’s human medicines committee recommended drugs to treat breast cancer, lupus nephritis, type 2 diabetes and more.
EMA Endorses Statement on International Collaboration of Real-World Evidence
A joint statement calling for international collaboration on the creation and use of real-world evidence has been published by the International Coalition of Medicines Regulatory Authorities.
MHRA Updates Guidance on Handling of Approved or Pending DCP and MRP
The new guidance outlines the approach the MHRA intends to take for products approved or pending in a decentralized procedure or mutual recognition procedures.
EMA Starts Rolling Review of Adapted COVID-19 Vaccines
The agency will review laboratory study and CMC data on the bivalent vaccine that targets two strains of the SARS-CoV-2 virus.
International Collaboration on Pharmaceutical Regulations
Lessons learned from the COVID-19 pandemic about the benefits of international collaboration were discussed in a May 2022 workshop.
MHRA to Play Greater Role in International Medicines Regulation
MHRA has been accepted as a full member of three international work-sharing partnerships aimed at making sure medicines and medical devices are regulated safely and efficiently across the world.
EMA Publishes 2021 Annual Report
In the report, the agency presents the activities it accomplished in 2021 to protect and promote public health.
EMA Adopts List of Critical COVID-19 Medicines
The agency’s Medicines Shortages Steering Group has adopted a list of critical COVID-19 vaccines and treatments so they may be monitored for potential shortages.
Vaxzevria Gains Approval in EU as a Third Dose COVID-19 Booster in Adults
AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.
EMA Recommends Approval of Niemann-Pick Disease Types A/B and B Therapy
EMA has recommended the marketing authorization of Xenpozyme (olipudase alfa) in the European Union.
The Data Relationship
As Europe moves closer to implementation of ISO IDMP standards, the bio/pharma industry is accelerating efforts to manage its data and documents more effectively.
EMA’s PRIME Enables Earlier Availability of Life-Changing Medicines
EMA’s PRIME scheme has enabled life-changing medicines to become available to patients at a faster rate.
EMA Recommends Approval of Spikevax for Children Aged 6 to 11
EMA has recommended approval of Spikevax for children aged 6 to 11.
New Medicines Recommendations Up in 2021, EMA States
The agency recommended 53 new active substances in 2021, up 35% from 2020.
EMA Investigating Reports of Menstrual Irregularities with COVID-19 Vaccines
The agency’s safety committee is assessing reported cases of period irregularities associated with Comirnaty and Spikevax mRNA vaccines.
EMA Updates Guidance on Risk Management Plans for COVID-19 Vaccines
Guidance published during the pandemic has been updated to include content requirements for summary safety reports.
EMA Considers Adolescent Booster-Dose Application for Comirnaty
EMA has started its evaluation of an application for the use of a booster dose of Comirnaty in adolescents aged 12–15 years.
EMA Initiates DARWIN EU Coordination Centre
EMA has started the establishment of its Data Analysis and Real World Interrogation Network (DARWIN EU) Coordination Centre.
COVID-19 Vaccines Safe for Use During Pregnancy, EMA States
The agency’s COVID-19 task force says latest data shows use of COVID-19 mRNA vaccines during pregnancy is safe.
EMA Recommends Conditional Authorization for Novavax’s COVID-19 Vaccine
The agency recommended granting conditional marketing authorization for use of Nuvaxovid in people 18 years of age and older.
Looking Past the Pandemic: The Future of GMPs in Aseptic Processing
While supply chain disruptions have resulted in many alterations to workplace practices, they have also presented an opportunity to get ahead of changes to the EU’s upcoming revision of Annex 1.
Evolution of Aseptic Processing: INTERPHEX Keynote Part 5
Jordi Serrat, Product & Technology Director, Azbil Telstar talks about the role of disruptive and digital technologies in aseptic processing.
Evolution of Aseptic Processing: INTERPHEX Keynote Part 4
Rafael Beaus, Global Consultancy Manager, Azbil Telstar, discusses Annex 1 and trends in aseptic production.
Evolution of Aseptic Processing: INTERPHEX Keynote Part 3
Luke Stockhausen, Lead Process Engineer, CRB, talks about technological advances, processing line changes, and new solutions to overcome challenges in aseptic processing.
Evolution of Aseptic Processing: INTERPHEX Keynote Part 2
Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG, discusses the evolution of aseptic processing with a particular focus on isolators.